Incompatible live-donor kidney transplantation in the United States: results of a national survey (scientific article (publication date: August 2011))

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial

Q34373536

Domino paired kidney donation: a strategy to make best use of live non-directed donation

Q34552370

Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies.

Q35611406

Japanese experience of ABO-incompatible living kidney transplantation

Q37046521

ABO incompatible renal transplantation: a paradigm ready for broad implementation

Q37454277

The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline.

Q37644840

ABO-incompatible kidney transplantation using both A2 and non-A2 living donors

Q44077744

Positive cross-match living donor kidney transplantation: longer-term outcomes

Q46134337

Rituximab and intravenous immune globulin for desensitization during renal transplantation

Q46477840

ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up

Q46518667

ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment

Q46702772

Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation

Q46735702

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

Q50654391

Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation.

Q50984356

Kidney paired donation and optimizing the use of live donor organs.

Q51975686

A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.

Q53639822

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

Q55034268

Pre-Transplant Assessment of Donor-Reactive, HLA-Specific Antibodies in Renal Transplantation: Contraindication vs. Risk

Q59314397

A Comparison of Populations Served by Kidney Paired Donation and List Paired Donation

Q63185961

Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients

Q79347395

Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan

Q80198398

Utilizing list exchange and nondirected donation through 'chain' paired kidney donations

Q80281200

Donor kidney exchanges

Q80563244

Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation

Q82732578

A flexible national living donor kidney exchange program taking advantage of a central histocompatibility laboratory: the Dutch model

Q84476014

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

United States of America

Q30

kidney transplantation

Q740909

P304

page(s)

2041-6

P577

publication date

2011-08-01

P1433

published in

Clinical Journal of the American Society of Nephrology

Q15757929

P1476

title

Incompatible live-donor kidney transplantation in the United States: results of a national survey

P478

volume

Reverse relations

cites work (P2860)

Q35524699	ABO-incompatible renal transplantation: From saline flushes to antigen-specific immunoadsorption-Tools to overcome the barrier
Q38267202	An update on ABO-incompatible kidney transplantation
Q57122984	Anti A/B Antibody Titer Rebound: Are we Making it Worse? Be Aware of Your Intravenous Immunoglobulin
Q27009997	Biologics in renal transplantation
Q37138338	Cancer risk after ABO-incompatible living-donor kidney transplantation
Q35543289	Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients.
Q64084651	Early hospital readmissions after ABO- or HLA- incompatible living donor kidney transplantation
Q30276550	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue
Q36612789	Human leukocyte antigen antibody incompatible renal transplantation
Q38022711	Identification and therapeutic management of highly sensitized patients undergoing renal transplantation.
Q36126901	Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients
Q38036246	Incompatible kidney transplantation: a brief overview of the past, present and future.
Q38006827	Innovative strategies in living donor kidney transplantation
Q35715908	Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation
Q57224820	Kidney transplantation after desensitization in sensitized patients: a Korean National Audit
Q50137555	Landscape of ABO-Incompatible Live Donor Kidney Transplantation in the US.
Q37147724	Order of donor type in pediatric kidney transplant recipients requiring retransplantation
Q44265489	Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients
Q35007419	Quantifying renal allograft loss following early antibody-mediated rejection.
Q44753304	Quantifying the risk of incompatible kidney transplantation: a multicenter study.
Q38208788	Results from a horizon scan on risks associated with transplantation of human organs, tissues and cells: from donor to patient
Q92469286	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial
Q40390324	Sense and sensitivity: incompatible patients and their donors in kidney transplantation
Q63185862	Temporal changes in the composition of a large multicenter kidney exchange clearinghouse: Do the hard-to-match accumulate?
Q38726037	The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis
Q33874032	The UK National Registry of ABO and HLA Antibody Incompatible Renal Transplantation: Pretransplant Factors Associated With Outcome in 879 Transplants
Q47553136	Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis
Q38133469	Transplant certification and quality assessment: time to take the front line?
Q91819183	Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study
Q102319264	Urgent therapeutic plasma exchange